These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18310916)

  • 21. Pharmacokinetics of doxorubicin and epirubicin in mice during chlorpromazine-induced hypothermia.
    Lundgren-Eriksson L; Carlsson A; Eksborg S; Ryd W; Vesanen R; Hultborn R
    Cancer Chemother Pharmacol; 1997; 40(5):419-24. PubMed ID: 9272119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis.
    Ikeda M; Okusaka T; Ueno H; Morizane C; Iwasa S; Hagihara A; Kojima Y
    Oncology; 2007; 72(3-4):188-93. PubMed ID: 18097170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic arterial injection chemotherapy for hepatocellular carcinoma with epirubicin aqueous solution as numerous vesicles in iodinated poppy-seed oil microdroplets: clinical application of water-in-oil-in-water emulsion prepared using a membrane emulsification technique.
    Higashi S; Setoguchi T
    Adv Drug Deliv Rev; 2000 Dec; 45(1):57-64. PubMed ID: 11104897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.
    Dobbs NA; Twelves CJ; Gregory W; Cruickshanka C; Richards MA; Rubens RD
    Eur J Cancer; 2003 Mar; 39(5):580-6. PubMed ID: 12628836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A pharmacokinetic study of intra-arterial chemotherapy for prophylactic treatment of liver metastasis after hepatectomy for liver cancer].
    Umekita N; Awane Y; Maeshiro T; Miyamoto S; Yamada F; Matsumine T
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1544-6. PubMed ID: 1530304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Results of clinical study with epirubicin hydrochloride injectable solution in hepatoma].
    Monden M; Nakamura H; Yayoi E; Monden T; Ohi H; Arisawa J; Masuzawa M; Shimizu T; Tomono N; Seki K; Nakao N; Todo A; Inoue Y; Sakon M; Ohsaki Y; Hosoki T
    Gan To Kagaku Ryoho; 1998 Sep; 25(11):1713-9. PubMed ID: 9757197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology.
    Müller HJ; Grubert M; Hilger R; Richly H; Port R; Scheulen M; Mross K;
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):575-7. PubMed ID: 12503820
    [No Abstract]   [Full Text] [Related]  

  • 28. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
    Esposito M; Venturini M; Vannozzi MO; Tolino G; Lunardi G; Garrone O; Angiolini C; Viale M; Bergaglio M; Del Mastro L; Rosso R
    J Clin Oncol; 1999 Apr; 17(4):1132. PubMed ID: 10561171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional pharmacokinetics of doxorubicin following hepatic arterial and portal venous administration: evaluation with hepatic venous isolation and charcoal hemoperfusion.
    Iwasaki T; Ku Y; Kusunoki N; Tominaga M; Fukumoto T; Muramatsu S; Kuroda Y
    Cancer Res; 1998 Aug; 58(15):3339-43. PubMed ID: 9699664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity.
    Yang F; Lei Q; Li L; He JC; Zeng J; Luo C; Yeung SJ; Yang R
    PLoS One; 2017; 12(11):e0188025. PubMed ID: 29131861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4'-epidoxorubicin in rats.
    Hall KS; Endresen L; Schjerven L; Rugstad HE
    Cancer Chemother Pharmacol; 1990; 26(6):444-8. PubMed ID: 2225316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms.
    Lilienberg E; Ebeling Barbier C; Nyman R; Hedeland M; Bondesson U; Axén N; Lennernäs H
    Mol Pharm; 2014 Jan; 11(1):131-44. PubMed ID: 24171458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined therapy with external beam irradiation and hepatic arterial epirubicin infusion through an implanted port for advanced hepatocellular carcinoma.
    Takizawa K; Honda M; Obuchi M; Hasebe S; Matsuoka S; Yamada M; Kuniyasu Y
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-116-S6-121. PubMed ID: 9151926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres.
    Sottani C; Poggi G; Quaretti P; Regazzi M; Montagna B; Quaquarini E; Imbriani M; Leoni E; Di Cesare P; Riccardi A; Bernardo G; Minoia C
    Anticancer Res; 2012 May; 32(5):1769-74. PubMed ID: 22593459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma.
    Bhattacharya S; Novell JR; Dusheiko GM; Hilson AJ; Dick R; Hobbs KE
    Cancer; 1995 Dec; 76(11):2202-10. PubMed ID: 8635022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
    Lo YL; Liu Y; Tsai JC
    Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacokinetics of epirubicin hydrochloride long-circulating thermosensitive liposomes in rat plasma].
    Wu Y; Zhang FC; Wu C; Mei XG; Lü WL
    Yao Xue Xue Bao; 2010 Mar; 45(3):365-70. PubMed ID: 21351514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the effect of adjusting epirubicin doses for body surface area?
    Dobbs NA; Twelves CJ
    Br J Cancer; 1998 Sep; 78(5):662-6. PubMed ID: 9744507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats.
    Simonsen LE; Wählby U; Sandström M; Freijs A; Karlsson MO
    Anticancer Res; 2000; 20(3A):1519-25. PubMed ID: 10928065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.